Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 3/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 3/20 | 0.42 |
| ▸ | TDO2 | P48775 | 3/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15951915 | 0.86 | CES2 (0.41) | OPRL1OPRM1OPRD1OPRK1IDO1 | |
| SCHEMBL3254640 | 0.86 | IDO1 (0.52) | OPRL1OPRM1OPRD1OPRK1IDO1 | |
| SCHEMBL3253159 | 0.86 | IDO1 (0.52) | OPRL1OPRM1OPRD1OPRK1IDO1 | |
| SCHEMBL12568799 | 0.86 | IDO1 (0.52) | OPRL1OPRM1OPRD1OPRK1IDO1 | |
| SCHEMBL17842140 | 0.85 | OPRL1 (0.43) | OPRL1OPRM1OPRD1OPRK1IDO1 | |
| SCHEMBL10630426 | 0.82 | IDO1 (0.46) | OPRL1OPRM1OPRD1OPRK1IDO1 | |
| SCHEMBL17519156 | 0.82 | OPRM1 (0.49) | OPRL1OPRM1OPRD1OPRK1IDO1 | |
| SCHEMBL17519159 | 0.79 | SLC7A5 (0.50) | OPRL1OPRM1IDO1TDO2DPP4 | |
| SCHEMBL22088893 | 0.78 | SLC1A1 (0.46) | OPRL1HDAC4HDAC7HDAC5CES2 | |
| SCHEMBL19696805 | 0.78 | SLC1A1 (0.46) | OPRL1HDAC4HDAC7HDAC5CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647702-B2 | Aryl-substituted imidazoles | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190345141-A1 | ARYL-SUBSTITUTED IMIDAZOLES | ST JUDE CHILDRENS RES HOSPITAL (US) | 2019-11-14 | — | — | US | disclosed |
| EP-2621275-B1 | ARYL-SUBSTITUTED IMIDAZOLES | ST JUDE CHILDRENS RES HOSPITAL (US) | 2018-03-28 | — | — | EP | disclosed |
| US-9822100-B2 | Aryl-substituted imidazoles | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2017-11-21 | — | — | US | disclosed |
| US-20160297800-A1 | ARYL-SUBSTITUTED IMIDAZOLES | ST JUDE CHILDREN'S RES HOSPITAL (US) | 2016-10-13 | — | — | US | disclosed |
| US-9266860-B2 | Aryl-substituted imidazoles | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2016-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345141-A1 | ARYL-SUBSTITUTED IMIDAZOLES | MDM2, TP53, MDM4 | OPRL1 3301/4885OPRM1 4184/4885OPRD1 4183/4885 |
| US-10647702-B2 | Aryl-substituted imidazoles | MDM2, TP53, MDM4 | OPRL1 3301/4885OPRM1 4184/4885OPRD1 4183/4885 |
| US-20160297800-A1 | ARYL-SUBSTITUTED IMIDAZOLES | MDM2, TP53, MDM4 | OPRL1 3301/4885OPRM1 4184/4885OPRD1 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.